The treatment of locoregionally advanced squamous cell carcinoma of the head and neck
(SCCHN) has evolved in recent years as a consequence of a better understanding of the …

Radiotherapy remains the foundation of current treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Purpose The role of cetuximab in the treatment of locoregionally advanced head and neck
squamous cell cancer (LA-HNSCC) remains poorly defined. In this phase 2 randomized …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

5529 Background: We previously reported results of a phase 2 study of concurrent
cetuximab, a chimeric monoclonal antibody directed against the epidermal growth factor …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …